METHYLGENE RESCHEDULES FULL YEAR 2008
CONFERENCE CALL TO APRIL 7TH

Montreal, Quebec. March 27, 2009 – MethylGene Inc. (TSX:MYG) today announced that due to
the death in the family of a member of senior management, the Company has rescheduled its fourth quarter and year end 2008 conference call and audio webcast to Tuesday, April 7, 2009 at 11:00 a.m. ET.

Interested parties may participate by dialing 416-644-3419 or 1-800-732-0232. The webcast will be available on the Company's website at www.methylgene.com. A question and answer session will follow formal remarks, at which time the operator will direct participants as to the correct procedures for submitting questions. A telephone replay of the conference call will be available from April 7th through April 14th, 2009. To access the replay, dial 416-640-1917 or 1-877-289-8525 and enter the reservation number 21302445#.

About MethylGene

MethylGene Inc. (TSX: MYG) is a publicly-traded, clinical stage, biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for cancer. The Company’s product candidates include: MGCD265, an oral, multi-targeted kinase inhibitor targeting the c-Met, VEGF, Tie-2 and Ron receptor tyrosine kinases that is in Phase I clinical trials for solid tumor cancers; MGCD290, a fungal Hos2 (HDAC) inhibitor being developed for use in combination with fluconazole for serious fungal infections that is also in Phase I clinical studies; and MGCD0103, an oral, isoform-selective HDAC inhibitor which has been in multiple clinical trials for solid tumors and hematological malignancies and is licensed to Taiho Pharmaceutical Co. Ltd. A fourth compound discovered using MethylGene’s HDAC platform, EVP-0334 - a potential cognition enhancing agent, is in a Phase I study sponsored by EnVivo Pharmaceuticals Inc. MethylGene also has a funded collaboration with Otsuka Pharmaceutical Co. Ltd. for applications in ocular diseases using the Company’s proprietary kinase inhibitor chemistry. Please visit our website at www.methylgene.com.

Investor Relations Contacts:
Rhonda Chiger Rx Communications Group, LLC Phone: 917-322-2569 rchiger@rxir.com	Donald F. Corcoran President & CEO MethylGene Inc. Phone: 514-337-3333 ext. 373 mctavishk@methylgene.com

Certain statements contained in this news release, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Such state